Laboratorios Farmaceuticos Rovi (XMAD:ROVI) LT-Debt-to-Total-Asset : 0.07 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Laboratorios Farmaceuticos Rovi's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.07.

Laboratorios Farmaceuticos Rovi's long-term debt to total assets ratio declined from Dec. 2022 (0.07) to Dec. 2023 (0.07). It may suggest that Laboratorios Farmaceuticos Rovi is progressively becoming less dependent on debt to grow their business.

Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset Chart

Laboratorios Farmaceuticos Rovi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.14

0.12

0.09

0.07

Laboratorios Farmaceuticos Rovi Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.06	0.06	0.07	-

Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset Calculation

Laboratorios Farmaceuticos Rovi's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	52.242	/	799.884
	=	0.07

Laboratorios Farmaceuticos Rovi's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	52.242	/	799.884
	=	0.07

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.